Comments
The US health regulator has completed inspection of Lupin’s Nagpur facility, which manufactures oral solid products, without making any observations.
In a BSE filing today, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations.’’
Shares of Lupin were trading up by 1.72 per cent at Rs 764.75 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.